Health News
Insight: In vulnerable Greece, mosquitoes bite back
ATHENS - Just when it seems things couldn't get any worse for Greece, the exhausted and indebted country has a new threat to deal with: mosquito-borne diseases.
FDA says meningitis probe could hit hospital drug supplies
- The extended shutdown of a sister company of the pharmacy at the center of the deadly meningitis outbreak may exacerbate drug shortages for some hospitals and healthcare providers, health regulators said.
Killer disease reaches Uganda capital, five dead
KAMPALA - An outbreak of the deadly Marburg virus in Uganda has spread to the capital Kampala after an infected woman travelled to the city and the death toll from the disease, a cousin of Ebola, climbed to five, a health official said on Monday.
Healthcare costs top U.S. executives' concerns: Adecco survey
NEW YORK - U.S. corporate executives are more worried about providing healthcare benefits to their employees than about issues like wages, taxes or attracting qualified workers, according to a survey by the world's No. 1 staffing company, Adecco SA.
Docs call for changes to prevent cheer injuries
NEW YORK (Reuters Health) - A group of U.S. pediatricians on Monday recommended that cheerleading be designated an official sport, mainly to help prevent injuries, which the doctors say can be catastrophic.
Monster Beverage tumbles on suit about girl's death
- Monster Beverage Corp shares fell 16 percent on Monday after news that it is being sued by the family of a 14-year-old girl who died after drinking two cans of its Monster Energy drink.
Pfizer to buy maker of attention-deficit drug for $255 million
- Pfizer Inc said it would buy privately held-NextWave Pharmaceuticals for $255 million, gaining access to the company's attention deficit hyperactivity disorder drug, the first once-daily liquid medicine approved to treat the condition in the United States.
Another Supernus epilepsy drug gets FDA nod
- Supernus Pharmaceuticals Inc's experimental epilepsy drug Oxtellar XR won marketing approval from the U.S. Food and Drug Administration, the second drug approval for the company since it went public in May.
Lilly's dulaglutide tops 3 diabetes drugs in late-stage trials
- Eli Lilly & Co's experimental once-weekly diabetes drug dulaglutide proved superior in late-stage clinical trials to three other widely used medicines that are dosed more frequently, the company said on Monday.
France says no need to revisit Monsanto maize approval
PARIS - A study last month pointing to health risks from a type of genetically modified maize and a related pesticide did not provide grounds for questioning previous safety approvals, the French government said on Monday.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
